Sharmin, Sifat, Lefort, Mathilde, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand'Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Andersen, Johanna Balslev, Trojano, Maria, McCombe, P, Slee, M, Lechner-Scott, Jeannette, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Prevost, J, Maimone, D, Leray, Emmanuelle, Skibina, O, Buzzard, K, Van der Walt, A, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Horakova, Dana, Ciron, J, Ruet, A, De Seze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frenay, C, Moreau, T, Berger, E, Havrdova, Eva Kubala, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Alroughani, Raed, Montcuquet, A, Wahab, A, Camdessanche, J-P, Maurousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Izquierdo, Guillermo, Laplaud, D, Koch-Henriksen, N, Sellebjerg, FT, Soerensen, PS, Pfleger, CC, Rasmussen, PV, Jensen, MB, Frederiksen, JL, Bramow, S, Mathiesen, HK, Ozakbas, Serkan, Schreiber, KI, Magyari, M, Vukusic, S, Butzkueven, H, Kalincik, T, Patti, Francesco. Adis International; 2021. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.